|
|
|
Volumn 10, Issue 8, 2005, Pages
|
|
The role of modified-release formulations in hypnotic therapy for insomnia
a a a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
BENZODIAZEPINE DERIVATIVE;
ESTAZOLAM;
ESZOPICLONE;
FLURAZEPAM;
HYPNOTIC SEDATIVE AGENT;
INDIPLON;
LITHIUM;
PAROXETINE;
QUAZEPAM;
TRIAZOLAM;
ZALEPLON;
ZOLPIDEM;
AGE DISTRIBUTION;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED DRUG RELEASE;
CORRELATION ANALYSIS;
DIABETES MELLITUS;
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS;
DRUG ABSORPTION;
DRUG BLOOD LEVEL;
DRUG ELIMINATION;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG INDICATION;
DRUG RELEASE;
EPIDEMIOLOGICAL DATA;
HUMAN;
HYPERTENSION;
IMPAIRED GLUCOSE TOLERANCE;
INFLAMMATION;
INSOMNIA;
LONGITUDINAL STUDY;
MORTALITY;
OBESITY;
PREVALENCE;
PRIORITY JOURNAL;
PSYCHOPHARMACOTHERAPY;
QUALITY OF LIFE;
RISK BENEFIT ANALYSIS;
SLEEP DEPRIVATION;
SLEEP PATTERN;
SLEEP TIME;
SLEEP WAKING CYCLE;
SUSTAINED RELEASE PREPARATION;
SYMPTOM;
|
|
EID: 24144458575
PISSN: 10928529
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (0)
|